Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 12

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date

Authors Kivelevitch D, Amin S, Menter A

Received 20 November 2018

Accepted for publication 13 March 2019

Published 24 April 2019 Volume 2019:12 Pages 249—253

DOI https://doi.org/10.2147/CCID.S165040

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg


Dario Kivelevitch,1 Sima Amin,2 Alan Menter1

1Baylor University Medical Center, Dallas, TX, USA; 2Texas A&M College of Medicine, Bryan, TX, USA

Abstract: Psoriasis is an immune-mediated inflammatory dermatosis commonly affecting the scalp and fringes of the face, neck and ears. It may be difficult to treat and the presence of extensive and highly visible lesions may significantly influence psychosocial well-being. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A and has been shown to provide robust and sustained efficacy for whole body psoriasis. In this review, we evaluate the evidence to date of secukinumab in patients with moderate-to-severe scalp psoriasis. A comprehensive Cochrane database and PubMed searches of all available literature in English through September 2018 was performed using the search terms: “psoriasis”, “scalp” and “secukinumab”. Based on current evidence, we conclude that secukinumab is efficacious and well-tolerated treatment for patients with moderate-to-severe scalp psoriasis. Further studies are however warranted.

Keywords: secukinumab, psoriasis, scalp, therapy


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]